AU7206891A - The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity - Google Patents

The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity

Info

Publication number
AU7206891A
AU7206891A AU72068/91A AU7206891A AU7206891A AU 7206891 A AU7206891 A AU 7206891A AU 72068/91 A AU72068/91 A AU 72068/91A AU 7206891 A AU7206891 A AU 7206891A AU 7206891 A AU7206891 A AU 7206891A
Authority
AU
Australia
Prior art keywords
pny
preparation
antagonistic activity
guanidine derivatives
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU72068/91A
Other versions
AU637882B2 (en
Inventor
Kurt Henning Dr Ahrens
Heidrun Dr. Engler
Martin C. Dr. Michel
Johann Peter Dr. Morsdorf
Helmut Dr. Schickaneder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heumann Pharma GmbH and Co
Original Assignee
Heumann Pharma GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma GmbH and Co filed Critical Heumann Pharma GmbH and Co
Publication of AU7206891A publication Critical patent/AU7206891A/en
Application granted granted Critical
Publication of AU637882B2 publication Critical patent/AU637882B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The use of guanidine derivatives with the basic framework <IMAGE> for the manufacture of a medicament with NPY-antagonistic activity and, in particular, for the manufacture of a medicament for the treatment of high blood pressure is described.
AU72068/91A 1990-03-30 1991-03-04 The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity Ceased AU637882B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90106200 1990-03-30
EP90106200A EP0448765B1 (en) 1990-03-30 1990-03-30 Use of guanidine derivatives for the manufacture of a medicament with NPY-antagonistic activity

Publications (2)

Publication Number Publication Date
AU7206891A true AU7206891A (en) 1991-10-03
AU637882B2 AU637882B2 (en) 1993-06-10

Family

ID=8203843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72068/91A Ceased AU637882B2 (en) 1990-03-30 1991-03-04 The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity

Country Status (14)

Country Link
EP (1) EP0448765B1 (en)
JP (1) JPH0789939A (en)
KR (1) KR910016329A (en)
AT (1) ATE109979T1 (en)
AU (1) AU637882B2 (en)
CA (1) CA2037433A1 (en)
DE (1) DE59006842D1 (en)
DK (1) DK0448765T3 (en)
ES (1) ES2058651T3 (en)
HU (1) HU207945B (en)
IE (1) IE65252B1 (en)
IL (1) IL97424A (en)
PT (1) PT97138A (en)
ZA (1) ZA911471B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012139A1 (en) * 1991-12-19 1993-06-24 Garvan Institute Of Medical Research A novel molecule which inhibits neuropeptide tyrosine biological function

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
AU7692996A (en) * 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
EP0912551A1 (en) * 1996-05-14 1999-05-06 Novo Nordisk A/S Somatostatin agonists and antagonists
US6849733B1 (en) * 1996-08-23 2005-02-01 Agouron Pharmaceuticals, Inc. Neuropeptide-Y ligands
FR2754709B1 (en) 1996-10-23 1999-03-05 Sanofi Sa COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION
ZA979701B (en) * 1996-10-31 1998-05-21 Novo Nordisk As Novo Nordisk A Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.
EP0927166A1 (en) * 1997-02-14 1999-07-07 Bayer Corporation Amides as npy5 receptor antagonists
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
CA2251368A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
EP0996443A1 (en) * 1997-07-03 2000-05-03 Neurogen Corporation Certain diarylimidazole derivatives; a new class of npy specific ligands
ES2161594B1 (en) * 1998-12-17 2003-04-01 Servier Lab NEW DERIVATIVES OF HYDRAZIDE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO2000066578A1 (en) 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
ES2233708T3 (en) 2000-09-20 2005-06-16 Schering Corporation IMIDAZOLS REPLACED AS AGONISTS OR DUAL ANTAGONISTS OF HISTAMINE H1 AND H3.
ES2311544T3 (en) 2000-09-20 2009-02-16 Schering Corp IMIDAZOLS REPLACED AS AGONISTS OR DUAL ANTAGONISTS OF HISTAMINE H1 AND H3.
AU2001292730A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
ES2313985T3 (en) 2000-09-20 2009-03-16 Schering Corporation IMIDAZOLS REPLACED AS AGONISTS OR ANTAGONISTS OF HISTAMINE H1 AND H3.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199845B1 (en) * 1985-04-02 1990-08-01 HEUMANN PHARMA GMBH &amp; CO Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them
DE3631334A1 (en) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co NEW IMIDAZOLYLGUANIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012139A1 (en) * 1991-12-19 1993-06-24 Garvan Institute Of Medical Research A novel molecule which inhibits neuropeptide tyrosine biological function

Also Published As

Publication number Publication date
AU637882B2 (en) 1993-06-10
HUT57044A (en) 1991-11-28
IE65252B1 (en) 1995-10-18
ZA911471B (en) 1991-11-27
EP0448765B1 (en) 1994-08-17
JPH0789939A (en) 1995-04-04
HU207945B (en) 1993-07-28
CA2037433A1 (en) 1991-10-01
PT97138A (en) 1991-11-29
EP0448765A1 (en) 1991-10-02
DK0448765T3 (en) 1994-09-19
IE910995A1 (en) 1991-10-09
ATE109979T1 (en) 1994-09-15
ES2058651T3 (en) 1994-11-01
DE59006842D1 (en) 1994-09-22
KR910016329A (en) 1991-11-05
HU910979D0 (en) 1991-10-28
IL97424A0 (en) 1992-06-21
IL97424A (en) 1995-05-26

Similar Documents

Publication Publication Date Title
AU7206891A (en) The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity
ATE163849T1 (en) MEDICINAL PRODUCTS CONTAINING R-ALPHA-LIPOIC ACID OR S-ALPHA-LIPOIC ACID AS THE ACTIVE INGREDIENTS
CA2041579A1 (en) Dosage form
IE802676L (en) Sulfonyl ureas.
DE69420412T2 (en) THERAPEUTIC INHALATION PRODUCT
ES2077530A1 (en) Pharmaceutical products for curing tumorous diseases and process for preparing same
ZA888461B (en) Azelastine-containing medicaments for application in the nose and/or at the eye
CS189391A3 (en) Dialkoxypiridylbenzimidazole derivatives, process of their preparation and their pharmaceutical use
AU1968992A (en) Preparation of fatty acid medicaments
AU650261B2 (en) Derivatives of glycinamide, their preparation and medicaments containing them
HU913137D0 (en) 2-amino-4-carboxamido-pirimidine derivatives, their production and medical use
AU8448091A (en) Novel polypeptide and anti-hiv drug prepared therefrom
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
ATE162076T1 (en) USE OF NADH AND NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE
USD318159S (en) Disposable container for hospital surgery room discards
CA2020346A1 (en) Antibiotic ge 2270 factors a1, a2, a3 and h
CA2037779A1 (en) Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
HU9201358D0 (en) 2-amino-pirimidine-4-carboxamide derivatives, process for their production and for the production of medical preparations containing them as active agents
EP0732401A3 (en) Megakaryocyte stimulating factor (meg-CSF)
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
IE831551L (en) Eye ointment.
NO307126B1 (en) Use of biologically active ureido derivatives for the manufacture of a medicament for use in the treatment of lentivirus-induced disease
EP0651741A1 (en) N?g -monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock.
AU4266089A (en) 3-aryloxymethyl-cephalosporin derivatives, their preparation and their medical use
EP0359062A3 (en) Antibiotic ge 2270